This study is not accepting new patients
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSD UCSF
- Dates
- study start
- Principal Investigator
- by Lyudmila Bazhenova (ucsd)Alain Algazi (ucsf)
Description
Summary
Details
Keywords
Eligibility
Locations
Lead Scientists at University of California Health
- Lyudmila Bazhenova (ucsd)
Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators. - Alain Algazi (ucsf)
Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.
Details
- Status
- not accepting new patients
- Start Date
- Sponsor
- Loxo Oncology, Inc.
- ID
- NCT03906331
- Study Type
- Expanded Access
- Last Updated